$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Comprehensive interpretation of the indications and clinical scope of sparsentan (sparsentan)
2026-02-01 22:25:32
Check Details
Ixazomib (Ixazomib) foreign generic drug prices and purchasing reference information
2026-02-01 22:25:32
Check Details
Rubitin/Rubicatin (Zanbega) Medication Guide and Safe Medication Operation Suggestions
2026-02-01 22:25:32
Check Details
How high is the cure rate of Axitinib (Inlida) and the key factors affecting its efficacy
2026-02-01 22:25:32
Check Details
Contraindications for using Trametinib (Megenin) and which patients are not suitable for taking it
2026-02-01 22:25:32
Check Details
Is avatrombopag (Sucoxin) suitable for patients with leukemia and thrombocytopenia?
2026-02-01 22:25:32
Check Details
Which type of leukemia is suitable for treatment with giritinib (segatan)?
2026-02-01 22:25:32
Check Details
How long does it take to see obvious therapeutic effects after taking Osimertinib (Tagressa)
2026-02-01 22:25:32
Check Details
Detailed instructions and patient medication guide for Eltrombopag (Revlan)
2026-02-01 22:25:32
Check Details
Is it necessary to take Loprostim (Huierning) continuously for a long time once it is used?
2026-02-01 22:25:32
Check Details
Differences and options between midostaurin and gilitinib in the treatment of leukemia
2026-02-01 22:25:32
Check Details
Is Cabergoline safe for long-term use and its potential effects on the body?
2026-02-01 22:25:32
Check Details
1
2
...
2231
2232
2233
2234
2235
2236
2237
...
10227
10228
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
2
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
3
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
4
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
5
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
6
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
7
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
8
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
9
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
10
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
11
Anagrelide vs. Hydroxyurea in Essential Thrombocythemia: Efficacy Profiles and Clinical Positioning
12
SCEMBLIX (Asciminib) Side Effect Management & Special Population Guide